All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
Score one for Hal Barron and the new R&D team steering GlaxoSmithKline’s pipeline.
The pharma giant reported this morning that its recently acquired PARP, Zejula ...
Increasingly influential drug cost-effectiveness watchdog ICER still doesn't think that the drugs approved to treat Duchenne muscular dystrophy have so far proved their value to patients. ...
If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS by John Carroll & team — all the news at 11:30a ET
EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET